Comparing heart imaging techniques for coronary artery disease
MyocardiAl CT Perfusion and Coronary Flow: a CompreHensive Cardiac CT Myocardial Perfusion Imaging (MPI)/Fractional Flow Reserve (FFR) and PET-CT MPI Evaluation (The MATCH Investigation)
This study is testing whether two new heart imaging methods, CT-MPI and CT-FFR, can give similar results to the traditional PET-MPI for people with coronary artery disease.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 20 (estimated) |
| Ages | 18 Years to 85 Years |
| Sex | All |
| Sponsor | Emory University Academic / other |
| Locations | 1 site (Atlanta, Georgia) |
| Trial ID | NCT04316676 on ClinicalTrials.gov |
What this trial studies
This project aims to evaluate and compare the effectiveness of CT myocardial perfusion imaging (CT-MPI) and CT fractional flow reserve (CT-FFR) against the traditional PET myocardial perfusion imaging (PET-MPI) in assessing coronary artery disease (CAD). Participants scheduled for PET-MPI will undergo both CT-MPI and CT-FFR to determine how well these newer imaging methods quantify myocardial perfusion and coronary flow. The study seeks to establish whether these non-invasive techniques can provide comparable results to the current gold standard, potentially improving diagnostic accuracy for CAD.
Who should consider this trial
Good fit: Ideal candidates are patients referred for clinically indicated CT-MPI for CAD assessment.
Not a fit: Patients who are pregnant or nursing, or those currently taking specific excluded medications may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to more accurate and less invasive diagnostic methods for patients with coronary artery disease.
How similar studies have performed: Other studies have shown promising results with similar imaging techniques, but this specific comparison is novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Referred for a clinically indicated CT-MPI for CAD assessment * Must provide written informed consent prior to any study-related procedures being performed * Must be willing to comply with all clinical study procedures Exclusion Criteria: * Pregnant or nursing females. The possibility of pregnancy will be excluded by testing (serum or urine ßHCG) within 24 hours before study agent administration, or if the woman has previous surgical sterilization, or if the woman is post menopausal, with minimum one (1) year history without menses. * Currently taking or has taken within 48 hours the following excluded medications: * ActoPlus Met (Pioglitazone + metformin) * Avandamet (Rosiglitazone + metformin) * Fortamet (metformin) * Glucovance (Glyburide +metformin) * Glucophage (metformin) * Glucophage extended-release (XR) (metformin) * Glumetza (metformin) * Janumet (Sitagliptin + metformin) * Metformin * Metaglip (Glipizide + metformin) * Riomet (metformin) * Implanted rhythm devices (pacemaker, defibrillator) * Acute psychiatric disorder * Unwilling to comply with the requirements of the protocol * Previously entered this study * Known hypersensitivity to iodinated contrast material, beta-blockers, or pharmaceutical stressors used in this study * Suffers from claustrophobia * Impaired renal function (GFR \< 45 ml/min) * Acute hypotension (\<100 mm Hg systolic) * 2nd or 3rd degree atrioventricular (AV) block
Where this trial is running
Atlanta, Georgia
- Emory University Hospital — Atlanta, Georgia, United States (Recruiting)
Study contacts
- Principal investigator: Carlo De Cecco, MD, PhD — Emory University
- Study coordinator: Carlo De Cecco
- Email: carlo.dececco@emory.edu
- Phone: 404-712-7968
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.